Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals Intl Inc (VRX) Stock: Here’s Why It Got Crushed

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) had an incredibly rough day on the market yesterday, and for good reason. The company reported its earnings for the third quarter, missing expectations on all fronts. Today, we’ll talk about what we saw from its earnings, how the stock reacted to the news, and what we can expect to see from VRX ahead. So, let’s get right to it…

VRX Misses The Mark With Earnings

As mentioned above, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) released its financial results for the third quarter yesterday. Here’s what we saw from the report.

stock, graph, low, crash, down, arrow, risk, fall, crack, price, bad, market, debt, statistics, sales, economy, decline, failure, red, loss, business, concept, diagram, rates,

Onypix/Shutterstock.com

– Earnings Per Share – In terms of earnings per share, VRX missed the mark in a big way. During the quarter, analysts expected that the company would generate earnings in the amount of $1.75 per share. However, the company actually reported earnings of $1.55 per share, missing expectations in a big way.

– Revenue – In terms of revenue, things didn’t get much better for VRX, as the company missed the mark there as well. During the third quarter, analysts expected that the company would generate revenue in the amount of $2.49 billion. However, the company actually reported revenue of $2.48 billion.

Along with the earnings was a statement issued by Joseph Papa, the Chairman and CEO at VRX. Here’s what he had to say…

This past quarter, we made further progress toward establishing the new Valeant…. We have, where appropriate, begun to centralize some parts of the business, and hired two key senior executives: Paul Herendeen, Chief Financial Officer, and Dr. Louis Yu, Chief Quality Officer. We also have started to present our financial results under three operating and reportable segments, which we believe will help clarify areas of strenght and provide additional transparency. While we have revised our expectations for the remainder of 2016, I continue to be encouraged by the commitment of our employees who work each day toward meeting our mission of helping improve people’s lives through our healthcare products.”

How The Market Reacted To The News

At the end of the day, investors are going to react to poor results in a negative way. That’s exactly what we saw from the stock yesterday. VRX closed the session at $14.98, after a loss of $4.05 per share or 21.28%.

What I’m Expecting To See Ahead

As each day passes, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is looking worse and worse. While there may be some opportunity here, that opportunity is overshadowed by pending legal actions as well as poor results. All in all, VRX is a big risk at the moment in my opinion.

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required


Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at CNAFinanceHelp@gmail.com!

Loading Comments...